A Peritoneal Granulomatous Lesion with Dense Histiocytic Infiltration Due to Nivolumab Treatment
Received Date : 21 May 2023
Accepted Date : 10 Sep 2023
Available Online : 02 Oct 2023
Doi: 10.37047/jos.2023-98050 - Article's Language: EN
J Oncol Sci.J Oncol Sci. 2023;9(3):184-8.
This is an open access article under the CC BY-NC-ND license
In the current practice of oncology, immunological treatments have an expanded spectrum owing to increased efficacy in various indications for the same tumor and the rising number of responsive cancers, by the novel agent development. In this report, the emergence of a peritoneal lesion is presented in a 50-year-old male patient under nivolumab treatment for lung adenocarcinoma. Granulomatous tissue with dense histiocytic infiltration and necrotic foci was revealed on histopathological examination. Immune-related granulomatous lesions are commonly defined as sarcoid-like and no necrosis, generally located in the mediastinal lymph nodes, lungs, and skin. To the best of our knowledge, this is the first report of an immune-related granulomatous lesion with histiocytic infiltration and necrotic foci, located on the peritoneum. The etiopathogenesis and clinicopathological features of immunotherapy-related granulomatous lesions and their potential predictive role on anticancer efficacy should be better understood.
  1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. Erratum in: N Engl J Med. 2010;363(13):1290. [Crossref]  [PubMed]  [PMC] 
  2. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330. [Crossref]  [PubMed] 
  3. Ciccarese C, Alfieri S, Santoni M, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(1):57-75. [Crossref]  [PubMed] 
  4. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375-2391. Erratum in: Ann Oncol. 2016;27(7):1362. [Crossref]  [PubMed]  [PMC] 
  5. Cornejo CM, Haun P, English J 3rd, Rosenbach M. Immune checkpoint inhibitors and the development of granulomatous reactions. J Am Acad Dermatol. 2019;81(5):1165-1175. [Crossref]  [PubMed] 
  6. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571. [Crossref]  [PubMed]  [PMC] 
  7. Ten Berge B, Paats MS, Bergen IM, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford). 2012;51(1):37-46. [Crossref]  [PubMed] 
  8. Zhang Y, Liu Z, Tian M, et al. The altered PD-1/PD-L1 pathway delivers the 'one-two punch' effects to promote the Treg/Th17 imbalance in pre-eclampsia. Cell Mol Immunol. 2018;15(7):710-723. [Crossref]  [PubMed]  [PMC] 
  9. Braun NA, Celada LJ, Herazo-Maya JD, et al. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Am J Respir Crit Care Med. 2014;190(5):560-571. [Crossref]  [PubMed]  [PMC] 
  10. Celada LJ, Rotsinger JE, Young A, et al. Programmed death-1 ınhibition of phosphatidylinositol 3-kinase/akt/mechanistic target of rapamycin signaling impairs sarcoidosis CD4+ T cell proliferation. Am J Respir Cell Mol Biol. 2017;56(1):74-82. [Crossref]  [PubMed]  [PMC] 
  11. Linke M, Pham HT, Katholnig K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293-302. [Crossref]  [PubMed]  [PMC] 
  12. Birnbaum MR, Ma MW, Fleisig S, et al. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep. 2017;3(3):208-211. [Crossref]  [PubMed]  [PMC] 
  13. Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology. 2016;5(12):e118. [Crossref]  [PubMed]  [PMC] 
  14. Seve P, Schott AM, Pavic M, Broussolle C, Gilis L, Thomas L. Sarcoidosis and melanoma: a referral center study of 1,199 cases. Dermatology. 2009;219(1):25-31. [Crossref]  [PubMed] 
  15. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, et al. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017;44(12):1080-1086. [Crossref]  [PubMed] 
  16. Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R. Pembrolizumab-associated sarcoidosis. JAAD Case Rep. 2016;2(4):290-293. [Crossref]  [PubMed]  [PMC] 
  17. Wu J, Kwong BY, Martires KJ, et al. Granuloma annulare associated with immune checkpoint inhibitors. J Eur Acad Dermatol Venereol. 2018;32(4):e124-e126. [Crossref]  [PubMed]  [PMC] 
  18. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol. 2015;33(28):3193-3198. [Crossref]  [PubMed]  [PMC] 
  19. Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS; MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675-1682. [Crossref]  [PubMed] 
  20. Beutler BD, Cohen PR. Sarcoidosis in melanoma patients: case report and literature review. Cancers (Basel). 2015;7(2):1005-1021. [Crossref]  [PubMed]  [PMC]